Hengrui Medicine (600276.SH): SHR-4595 for Injection Receives Drug Clinical Trial Approval Notice
Zhitong Finance APP News, Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Suzhou Shengdia Biopharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration regarding SHR-4595 for injection, and will soon initiate clinical trials.
Latest

